Tricyclic SpiroLactams Kill Mycobacteria In Vitro and In Vivo by Inhibiting Type II NADH Dehydrogenases

[Image: see text] It is critical that novel classes of antituberculosis drugs are developed to combat the increasing burden of infections by multidrug-resistant strains. To identify such a novel class of antibiotics, a chemical library of unique 3-D bioinspired molecules was explored revealing a pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Dam, Sushovan, Tangara, Salia, Hamela, Claire, Hattabi, Theo, Faïon, Léo, Carre, Paul, Antoine, Rudy, Herledan, Adrien, Leroux, Florence, Piveteau, Catherine, Eveque, Maxime, Flipo, Marion, Deprez, Benoit, Kremer, Laurent, Willand, Nicolas, Villemagne, Baptiste, Hartkoorn, Ruben C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791652/
https://www.ncbi.nlm.nih.gov/pubmed/36473699
http://dx.doi.org/10.1021/acs.jmedchem.2c01493

Ejemplares similares

Ejemplares similares